ASTRO Meeting In Brief
This article was originally published in The Gray Sheet
Executive Summary
Research and product news from the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting, held Oct. 28-31 in Boston
You may also be interested in...
ProNova Preps Its Next-Gen SC360 For Smaller, Cheaper Era Of Proton Therapy
The system, which developers hope to launch in the U.S. in 2015 following completion of a 510(k) submission to FDA, will cost about $50 million for a two-room configuration, and the gantry will weigh 15 tons, well under the typical 110-220-ton weight of most systems, according to ProNova.
Prostate Cancer Radiation Comparisons Support IMRT, Question Proton Therapy
A large Medicare database analysis provides support for intensity-modulated radiation therapy as the standard radiation tool for prostate cancer, while the nascent proton therapy showed no advantages.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”